Tag: licensing
-
Genetic Repair Company Starts-Up, Gains $87 Million
A company is getting underway to develop therapies that extend genome editing to repair genetic disruptions, not just remove them from DNA.
-
Genentech Gains Microbe Drug Discovery Tech in $1B Deal
Biotechnology company Genentech is licensing a process from a start-up enterprise that discovers small molecule drugs from naturally occurring microbes found in soil.
-
Univ. Spinoff Qualifies for NIH Clinical Program
An enterprise developing a synthetic antibody to treat breast cancer, spun-off from a University at Buffalo research lab, is taking part in a federal program to advance the treatments to clinical trials.
-
3-D Models Devised to Simulate Patients’ Tumors
A university lab is teaming up with a local biotechnology company to develop realistic models of tumors from individual cancer patients, enabling more personalized treatment options.
-
Stem Cell Eye Implants Safe, Stop Visual Function Loss
Early results from a clinical trial show implants of replacement retina cells grown from stem cells are safe for people with a form of age-related macular degeneration, and at least stop the loss of visual function.
-
Lilly, Cell Implants Start-Up Partner on Diabetes
Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases.
-
New Company Acquires Off-the-Shelf T-Cell Cancer Therapies
A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells.
-
Cough Suppressant Produced from Engineered Yeast Cells
A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast.
-
Antibodies Licensed for Multi-Target Immunotherapies
MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets.
-
Patent Awarded for Nanoparticle Drug, Cannabis Delivery
A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments.